Coenzyme Q10 Explained

Coenzyme Q10 (CoQ10 ) also known as ubiquinone, is a naturally occurring biochemical cofactor (coenzyme) and an antioxidant produced by the human body.[1] [2] [3] It can also be obtained from dietary sources, such as meat, fish, seed oils, vegetables, and dietary supplements.[1] [2] CoQ10 is found in many organisms, including animals and bacteria.

CoQ10 plays a role in mitochondrial oxidative phosphorylation, aiding in the production of adenosine triphosphate (ATP), which is involved in energy transfer within cells.[1] The structure of CoQ10 consists of a benzoquinone moiety and an isoprenoid side chain, with the "10" referring to the number of isoprenyl chemical subunits in its tail.[4] [5] [6]

Although a ubiquitous molecule in human tissues, CoQ10 is not a dietary nutrient and does not have a recommended intake level, and its use as a supplement is not associated with or approved for any health or anti-disease effect.[1] [2]

Biological functions

See also: Q cycle. CoQ10 is a component of the mitochondrial electron transport chain (ETC), where it plays a role in oxidative phosphorylation, a process required for the biosynthesis of adenosine triphosphate, the primary energy source of cells.[1] [6] [7]

CoQ10 is a lipophilic molecule that is located in all biological membranes of human body and serves as a component for the synthesis of ATP and is a life-sustaining cofactor for the three complexes (complex I, complex II, and complex III) of the ETC in the mitochondria.[1] [5] CoQ10 has a role in the transport of protons across lysosomal membranes to regulate pH in lysosome functions.[1]

The mitochondrial oxidative phosphorylation process takes place in the inner mitochondrial membrane of eukaryotic cells.[1] This membrane is highly folded into structures called cristae, which increase the surface area available for oxidative phosphorylation. CoQ10 plays a role in this process as an essential cofactor of the ETC located in the inner mitochondrial membrane and serves the following functions:[1] [7]

CoQ10 also may influence immune response by modulating the expression of genes involved in inflammation.[10] [11] [12]

Biochemistry

Coenzymes Q is a coenzyme family that is ubiquitous in animals and many Pseudomonadota,[13] a group of gram-negative bacteria. The fact that the coenzyme is ubiquitous gives the origin of its other name, ubiquinone.[1] [2] In humans, the most common form of coenzymes Q is coenzyme Q10, also called CoQ10 or ubiquinone-10.[1]

Coenzyme Q10 is a 1,4-benzoquinone, in which "Q" refers to the quinone chemical group and "10" refers to the number of isoprenyl chemical subunits (shown enclosed in brackets in the diagram) in its tail.[1] In natural ubiquinones, there are from six to ten subunits in the tail, with humans having a tail of 10 isoprene units (50 carbon atoms) connected to its benzoquinone "head".[1]

This family of fat-soluble substances is present in all respiring eukaryotic cells, primarily in the mitochondria.[1] Ninety-five percent of the human body's energy is generated this way.[14] Organs with the highest energy requirements—such as the heart, liver, and kidney—have the highest CoQ10 concentrations.[15] [16] [17] [18]

There are three redox states of CoQ: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol).[1] The capacity of this molecule to act as a two-electron carrier (moving between the quinone and quinol form) and a one-electron carrier (moving between the semiquinone and one of these other forms) is central to its role in the electron transport chain due to the iron–sulfur clusters that can only accept one electron at a time, and as a free radical–scavenging antioxidant.[1]

Deficiency

There are two major pathways of deficiency of CoQ10 in humans: reduced biosynthesis, and increased use by the body.[10] [19] Biosynthesis is the major source of CoQ10. Biosynthesis requires at least 15 genes, and mutations in any of them can cause CoQ deficiency.[19] CoQ10 levels also may be affected by other genetic defects (such as mutations of mitochondrial DNA, ETFDH, APTX, FXN, and BRAF, genes that are not directly related to the CoQ10 biosynthetic process).[19] Some of these, such as mutations in COQ6, can lead to serious diseases such as steroid-resistant nephrotic syndrome with sensorineural deafness.[20] [21] [22]

Assessment

Although CoQ10 may be measured in blood plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and blood mononuclear cells.[23] Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labeled p-hydroxybenzoate.[24]

Statins

Although statins may reduce CoQ10 in the blood it is unclear if they reduce CoQ10 in muscle. Evidence does not support that supplementation improves side effects from statins.[25] [26]

Chemical properties

The oxidized structure of CoQ10 is shown below. The various kinds of coenzyme Q may be distinguished by the number of isoprenoid subunits in their side-chains. The most common coenzyme Q in human mitochondria is CoQ10.[1] Q refers to the quinone head and "10" refers to the number of isoprene repeats in the tail. The molecule below has three isoprenoid units and would be called Q3.

In its pure state, it is an orange-colored lipophile powder, and has no taste nor odor.

Biosynthesis

Biosynthesis occurs in most human tissue. There are three major steps:

  1. Creation of the benzoquinone structure (using phenylalanine or tyrosine, via 4-hydroxybenzoate)
  2. Creation of the isoprene side chain (using acetyl-CoA)
  3. The joining or condensation of the above two structures

The initial two reactions occur in mitochondria, the endoplasmic reticulum, and peroxisomes, indicating multiple sites of synthesis in animal cells.[27]

An important enzyme in this pathway is HMG-CoA reductase, usually a target for intervention in cardiovascular complications. The "statin" family of cholesterol-reducing medications inhibits HMG-CoA reductase. One possible side effect of statins is decreased production of CoQ10, which may be connected to the development of myopathy and rhabdomyolysis. However, the role statins play in CoQ deficiency is controversial. Although statins reduce blood levels of CoQ, studies on the effects of muscle levels of CoQ are yet to come. CoQ supplementation also does not reduce side effects of statin medications.[23] [25]

Genes involved include PDSS1, PDSS2, COQ2, and ADCK3 (COQ8, CABC1).[28]

Organisms other than humans produce the benzoquinone and isoprene structures from somewhat different source chemicals. For example, the bacteria E. coli produces the former from chorismate and the latter from a non-mevalonate source. The common yeast S. cerevisiae, however, derives the former from either chorismate or tyrosine and the latter from mevalonate. Most organisms share the common 4-hydroxybenzoate intermediate, yet again uses different steps to arrive at the "Q" structure.[29]

Dietary supplement

Although neither a prescription drug nor an essential nutrient, CoQ10 is commonly used as a dietary supplement with the intent to prevent or improve disease conditions, such as cardiovascular disorders.[2] [30] CoQ10 is naturally produced by the body and plays a crucial role in cell growth and protection.[6] Despite its significant role in the body, it is not used as a drug for the treatment of any specific disease.[1] [2] [3]

Nevertheless, CoQ10 is widely available as an over-the-counter dietary supplement and is recommended by some healthcare professionals, despite a lack of definitive scientific evidence supporting these recommendations.[1] [3]

Regulation and composition

CoQ10 is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition.[31] [32] However, it is sold as a dietary supplement not subject to the same regulations as medicinal drugs, and is an ingredient in some cosmetics.[33] The manufacture of CoQ10 is not regulated, and different batches and brands may vary significantly.

Research

A 2014 Cochrane review found insufficient evidence to make a conclusion about its use for the prevention of heart disease.[34] A 2016 Cochrane review concluded that CoQ10 had no effect on blood pressure.[35] A 2021 Cochrane review found "no convincing evidence to support or refute" the use of CoQ10 for the treatment of heart failure.[36]

A 2017 meta-analysis of people with heart failure 30–100 mg/d of CoQ10 found a 31% lower mortality and increased exercise capacity, with no significant difference in the endpoints of left heart ejection fraction.[37] A 2021 meta-analysis found that coenzyme Q10 was associated with a 31% lower all-cause mortality in HF patients.[38] In a 2023 meta-analysis of older people, ubiquinone had evidence of a cardiovascular effect, but ubiquinol did not.[39]

Although CoQ10 has been used to treat purported muscle-related side effects of statin medications, a 2015 meta-analysis found that CoQ10 had no effect on statin myopathy.[40] A 2018 meta-analysis concluded that there was preliminary evidence for oral CoQ10 reducing statin-associated muscle symptoms, including muscle pain, muscle weakness, muscle cramps and muscle tiredness.[41]

Pharmacology

Absorption

CoQ10 in the pure form is a crystalline powder insoluble in water. Absorption as a pharmacological substance follows the same process as that of lipids; the uptake mechanism appears to be similar to that of vitamin E, another lipid-soluble nutrient.[18] This process in the human body involves secretion into the small intestine of pancreatic enzymes and bile, which facilitates emulsification and micelle formation required for absorption of lipophilic substances.[42] Food intake (and the presence of lipids) stimulates bodily biliary excretion of bile acids and greatly enhances absorption of CoQ10. Exogenous CoQ10 is absorbed from the small intestine and is best absorbed if taken with a meal. Serum concentration of CoQ10 in fed condition is higher than in fasting conditions.[43] [44]

Metabolism

CoQ10 is metabolized in all tissues, with the metabolites being phosphorylated in cells.[2] CoQ10 is reduced to ubiquinol during or after absorption in the small intestine.[2] It is absorbed by chylomicrons, and redistributed in the blood within lipoproteins.[2] Its elimination occurs via biliary and fecal excretion.[2]

Pharmacokinetics

Some reports have been published on the pharmacokinetics of CoQ10. The plasma peak can be observed 6–8 hours after oral administration when taken as a pharmacological substance.[2] In some studies, a second plasma peak also was observed at approximately 24 hours after administration, probably due to both enterohepatic recycling and redistribution from the liver to circulation.

Deuterium-labeled crystalline CoQ10 was used to investigate pharmacokinetics in humans to determine an elimination half-time of 33 hours.[45]

Bioavailability

In contrast to intake of CoQ10 as a constituent of food, such as nuts or meat, from which CoQ10 is normally absorbed, there is a concern about CoQ10 bioavailability when it is taken as a dietary supplement.[46] [47] Bioavailability of CoQ10 supplements may be reduced due to the lipophilic nature of its molecule and large molecular weight.[46]

Reduction of particle size

Nanoparticles have been explored as a delivery system for various drugs, such as improving the oral bioavailability of drugs with poor absorption characteristics.[48] However, this has not proved successful with CoQ10, although reports have differed widely.[49] [50] The use of aqueous suspension of finely powdered CoQ10 in pure water also reveals only a minor effect.[51]

Water-solubility

Facilitating drug absorption by increasing its solubility in water is a common pharmaceutical strategy and also has been shown to be successful for CoQ10. Various approaches have been developed to achieve this goal, with many of them producing significantly better results over oil-based softgel capsules in spite of the many attempts to optimize their composition. Examples of such approaches are use of the aqueous dispersion of solid CoQ10 with the polymer tyloxapol,[52] formulations based on various solubilising agents, such as hydrogenated lecithin,[53] and complexation with cyclodextrins; among the latter, the complex with β-cyclodextrin has been found to have highly increased bioavailability[54] [55] and also is used in pharmaceutical and food industries for CoQ10-fortification.

Adverse effects and precautions

Generally, oral CoQ10 supplementation is well tolerated.[1] The most common side effects are gastrointestinal symptoms (nausea, vomiting, appetite suppression, and abdominal pain), rashes, and headaches.[56] Some adverse effects, largely gastrointestinal, are reported with intakes.[2] Doses of 100–300 mg per day may induce insomnia or elevate liver enzymes.[2] The observed safe level risk assessment method indicated that the evidence of safety is acceptable at intakes up to 1200 mg per day.[57]

Use of CoQ10 supplementation is not recommended in people with liver or kidney disease, during pregnancy or breastfeeding, or in the elderly.[2]

Potential drug interactions

CoQ10 taken as a pharmacological substance has potential to inhibit the effects of theophylline as well as the anticoagulant warfarin; CoQ10 may interfere with warfarin's actions by interacting with cytochrome p450 enzymes thereby reducing the INR, a measure of blood clotting.[58] The structure of CoQ10 is similar to that of vitamin K, which competes with and counteracts warfarin's anticoagulation effects. CoQ10 is not recommended in people taking warfarin due to the increased risk of clotting.[56]

Dietary concentrations

Detailed reviews on occurrence of CoQ10 and dietary intake were published in 2010.[59] Besides the endogenous synthesis within organisms, CoQ10 also is supplied by various foods.[1] CoQ10 concentrations in various foods are:[1]

Food !! CoQ10 concentration (mg/kg)
Vegetable oils54–280
40–160
64–73
4–15
64–73
Beefheart 113
liver 39–50
muscle 26–40
Porkheart 12–128
liver 23–54
muscle 14–45
Chickenbreast 8–17
thigh24–25
wing11
Fish5–64
mackerel – red flesh43–67
mackerel – white flesh 11–16
4–8
5
Nuts27
19
18–23
20
17
5–14
Vegetables8–26
6–9
2–7
up to 10
2–5
Fruit10
3
6–7
1
1–2
1
1
1

Vegetable oils, meat and fish are quite rich in CoQ10 levels.[1] Dairy products are much poorer sources of CoQ10 than animal tissues. Among vegetables, broccoli and cauliflower are good sources of CoQ10.[1] Most fruit and berries are poor sources of CoQ10, with the exception of avocados, which have a relatively high oil and CoQ10 content.

Intake

In the developed world, the estimated daily intake of CoQ10 has been determined at 3–6 mg per day, derived primarily from meat.

South Koreans have an estimated average daily CoQ (Q9 + Q10) intake of 11.6 mg/d, derived primarily from kimchi.[60]

Effect of heat and processing

Cooking by frying reduces CoQ10 content by 14–32%.[61]

History

In 1950, a small amount of CoQ10 was isolated from the lining of a horse's gut, a compound initially called substance SA, but later deemed to be quinone found in many animal tissues.[62] In 1957, the same compound was isolated from mitochondrial membranes of beef heart, with research showing that it transported electrons within mitochondria. It was called Q-275 as a quinone.[62] [63] The Q-275/substance SA was later renamed ubiquinone as it was a ubiquitous quinone found in all animal tissues.[62] In 1958, its full chemical structure was reported.[62] [64] Ubiquinone was later called either mitoquinone or coenzyme Q due to its participation to the mitochondrial electron transport chain.[62] In 1966, a study reported that reduced CoQ6 was an effective antioxidant in cells.[65]

See also

Notes and References

  1. Web site: Coenzyme Q10 . Micronutrient Information Center, Linus Pauling Institute, Oregon State University . 13 April 2024 . 2018 . 15 March 2024 . https://web.archive.org/web/20240315190507/https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-Q10 . live .
  2. Web site: Sood B, Preeti Patel P, Keenaghan M . Coenzyme Q10 . StatPearls, US National Library of Medicine . 17 April 2024 . 30 January 2024 . 30285386 . 2 October 2023 . https://web.archive.org/web/20231002122139/https://ncbi.nlm.nih.gov/books/NBK531491/ . live .
  3. Web site: Coenzyme Q10 . National Center for Complementary and Integrative Health, US National Institutes of Health . 13 April 2024 . January 2019 . 4 April 2024 . https://web.archive.org/web/20240404222534/https://www.nccih.nih.gov/health/coenzyme-q10 . live .
  4. Mantle D, Lopez-Lluch G, Hargreaves IP . Coenzyme Q10 Metabolism: A Review of Unresolved Issues . International Journal of Molecular Sciences . 24 . 3 . 2585 . January 2023 . 36768907 . 9916783 . 10.3390/ijms24032585 . free .
  5. 10.1007/s40495-021-00273-6 . The Impact of Coenzyme Q10 on Neurodegeneration: A Comprehensive Review . 2022 . Current Pharmacology Reports . 8 . 1–19 . Kadian M, Sharma G, Pandita S, Sharma K, Shrivasatava K, Saini N, Kumar A .
  6. Mantle D, Heaton RA, Hargreaves IP . Coenzyme Q10 and Immune Function: An Overview . Antioxidants . 10 . 5 . 759 . May 2021 . 34064686 . 8150987 . 10.3390/antiox10050759 . free .
  7. Pradhan N, Singh C, Singh A . Coenzyme Q10 a mitochondrial restorer for various brain disorders . Naunyn Schmiedebergs Arch Pharmacol . 394 . 11 . 2197–2222 . November 2021 . 34596729 . 10.1007/s00210-021-02161-8.
  8. Manzar H, Abdulhussein D, Yap TE, Cordeiro MF . Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain . Int J Mol Sci . 21 . 23 . December 2020 . 9299 . 33291255 . 7730520 . 10.3390/ijms21239299 . free.
  9. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F . Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement . J Clin Med . 9 . 5 . April 2020 . 1266 . 32349341 . 7287951 . 10.3390/jcm9051266 . free.
  10. Hargreaves I, Heaton RA, Mantle D . Disorders of Human Coenzyme Q10 Metabolism: An Overview . Int J Mol Sci . 21 . 18 . September 2020 . 6695 . 32933108 . 7555759 . 10.3390/ijms21186695 . free.
  11. Mantle D, Millichap L, Castro-Marrero J, Hargreaves IP . Primary Coenzyme Q10 Deficiency: An Update . Antioxidants . 12 . 8 . August 2023 . 1652 . 37627647 . 10451954 . 10.3390/antiox12081652 . free.
  12. Barcelos IP, Haas RH . CoQ10 and Aging . Biology . 8 . 2 . May 2019 . 28 . 31083534 . 6627360 . 10.3390/biology8020028 . free.
  13. Nowicka B, Kruk J . Occurrence, biosynthesis and function of isoprenoid quinones . Biochimica et Biophysica Acta (BBA) - Bioenergetics . 1797 . 9 . 1587–1605 . September 2010 . 20599680 . 10.1016/j.bbabio.2010.06.007 . free .
  14. Ernster L, Dallner G . Biochemical, physiological and medical aspects of ubiquinone function . Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease . 1271 . 1 . 195–204 . May 1995 . 7599208 . 10.1016/0925-4439(95)00028-3 . free .
  15. Okamoto T, Matsuya T, Fukunaga Y, Kishi T, Yamagami T . Human serum ubiquinol-10 levels and relationship to serum lipids . International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition . 59 . 3 . 288–292 . 1989 . 2599795 .
  16. Aberg F, Appelkvist EL, Dallner G, Ernster L . Distribution and redox state of ubiquinones in rat and human tissues . Archives of Biochemistry and Biophysics . 295 . 2 . 230–234 . June 1992 . 1586151 . 10.1016/0003-9861(92)90511-T .
  17. Shindo Y, Witt E, Han D, Epstein W, Packer L . Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin . The Journal of Investigative Dermatology . 102 . 1 . 122–124 . January 1994 . 8288904 . 10.1111/1523-1747.ep12371744 .
  18. Žmitek J, ŽMitek K, Pravs I. Improving the bioavailability of coenzyme q10 from theory to practice. 2008. Agro Food Industry Hi-Tech. 5 April 2024. 23 April 2024. https://web.archive.org/web/20240423075336/https://www.scopus.com/record/display.uri?eid=2-s2.0-53849139131&origin=inward&txGid=4f4a035686dfee6b6fbde3099b06b518. live.
  19. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L . Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency . J Inherit Metab Dis . 38 . 1 . 145–56 . January 2015 . 25091424 . 10.1007/s10545-014-9749-9 .
  20. 10.1172/JCI45693 . COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness . 2011 . Journal of Clinical Investigation . 121 . 5 . 2013–2024 . 21540551 . 3083770 . Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rötig A, Nürnberg G, Becker C .
  21. 10.1002/jmd2.12068 . COQ6 mutation in patients with nephrotic syndrome, sensorineural deafness, and optic atrophy . 2020 . Jimd Reports . 54 . 1 . 37–44 . 32685349 . 7358665 . Justine Perrin R, Rousset-Rouvière C, Garaix F, Cano A, Conrath J, Boyer O, Tsimaratos M .
  22. Web site: Nephrotic Syndrome - COQ6 Associated (Concept Id: C4054393) - MedGen - NCBI . 6 April 2024 . 6 April 2024 . https://web.archive.org/web/20240406102811/https://www.ncbi.nlm.nih.gov/medgen/886260 . live .
  23. Trevisson E, DiMauro S, Navas P, Salviati L . Coenzyme Q deficiency in muscle . Current Opinion in Neurology . 24 . 5 . 449–456 . October 2011 . 21844807 . 10.1097/WCO.0b013e32834ab528 . free . 10261/129020 .
  24. Montero R, Sánchez-Alcázar JA, Briones P, Hernández AR, Cordero MD, Trevisson E, Salviati L, Pineda M, García-Cazorla A, Navas P, Artuch R . Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes . Clinical Biochemistry . 41 . 9 . 697–700 . June 2008 . 18387363 . 10.1016/j.clinbiochem.2008.03.007 . free . 11577/2447079 .
  25. Tan JT, Barry AR . Coenzyme Q10 supplementation in the management of statin-associated myalgia . American Journal of Health-System Pharmacy . 74 . 11 . 786–793 . June 2017 . 28546301 . 10.2146/ajhp160714 . 3825396 . free .
  26. Kennedy . Cormac . Köller . Yasmin . Surkova . Elena . 2020-04-01 . Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis . Atherosclerosis . en . 299 . 1–8 . 10.1016/j.atherosclerosis.2020.03.006 . 32179207 . 9 July 2024 . 28 December 2022 . https://web.archive.org/web/20221228052518/https://linkinghub.elsevier.com/retrieve/pii/S0021915020301386 . live . free .
  27. Bentinger M, Tekle M, Dallner G . Coenzyme Q--biosynthesis and functions . Biochemical and Biophysical Research Communications . 396 . 1 . 74–79 . May 2010 . 20494114 . 10.1016/j.bbrc.2010.02.147 .
  28. Book: Espinós C, Felipo V, Palau F . Inherited Neuromuscular Diseases: Translation from Pathomechanisms to Therapies . 2009 . Springer . 978-90-481-2812-9 . 122ff . 4 January 2011.
  29. Meganathan R . Ubiquinone biosynthesis in microorganisms . FEMS Microbiology Letters . 203 . 2 . 131–139 . September 2001 . 11583838 . 10.1111/j.1574-6968.2001.tb10831.x . free .
  30. Arenas-Jal M, Suñé-Negre JM, García-Montoya E . Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges . Comprehensive Reviews in Food Science and Food Safety . 19 . 2 . 574–594 . March 2020 . 33325173 . 10.1111/1541-4337.12539 . free . 2445/181270 .
  31. Book: 26389329 . 2002 . PDQ Integrative, Alternative, and Complementary Therapies Editorial Board . Coenzyme Q10: Health Professional Version . ((PDQ Integrative, Alternative, and Complementary Therapies Editorial Board)) .
  32. Web site: Mitochondrial disorders in children: Co-enzyme Q10 . 28 March 2017 . nice.org.uk . National Institute for Health and Care Excellence . UK . 10 October 2019 . 10 October 2019 . https://web.archive.org/web/20191010120754/https://www.nice.org.uk/advice/es11/resources/mitochondrial-disorders-in-children-coenzyme-q10-pdf-1158110303173 . live .
  33. Hojerová J . [Coenzyme Q10--its importance, properties and use in nutrition and cosmetics] . Ceska a Slovenska Farmacie . 49 . 3 . 119–123 . May 2000 . 10953455 .
  34. Flowers N, Hartley L, Todkill D, Stranges S, Rees K . Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease . The Cochrane Database of Systematic Reviews . 2014 . 12 . CD010405 . 4 December 2014 . 25474484 . 9759150 . 10.1002/14651858.CD010405.pub2 .
  35. Ho MJ, Li EC, Wright JM . Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension . The Cochrane Database of Systematic Reviews . 2016 . 3 . CD007435 . March 2016 . 26935713 . 6486033 . 10.1002/14651858.CD007435.pub3 .
  36. Al Saadi T, Assaf Y, Farwati M, Turkmani K, Al-Mouakeh A, Shebli B, Khoja M, Essali A, Madmani ME . Coenzyme Q10 for heart failure . The Cochrane Database of Systematic Reviews . 2021 . 2 . CD008684 . February 2021 . 35608922 . 8092430 . 10.1002/14651858.CD008684.pub3 . Cochrane Heart Group .
  37. Lei L, Liu Y . Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials . BMC Cardiovascular Disorders . 17 . 1 . 196 . July 2017 . 28738783 . 5525208 . 10.1186/s12872-017-0628-9 . free .
  38. Khan . Muhammad Shahzeb . Khan . Fiza . Fonarow . Gregg C. . Sreenivasan . Jayakumar . Greene . Stephen J. . Khan . Safi U. . Usman . Muhammad Shariq . Vaduganathan . Muthiah . Fudim . Marat . Anker . Stefan D. . Butler . Javed . June 2021 . Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map . European Journal of Heart Failure . en . 23 . 9 . 1468–1476 . 10.1002/ejhf.2278 . 34173307 . 1388-9842 . 10 June 2024 . 2 January 2023 . https://web.archive.org/web/20230102122936/https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2278 . live .
  39. Fladerer JP, Grollitsch S . Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality . Current Cardiology Reports . 25 . 12 . 1759–1767 . December 2023 . 37971634 . 10811087 . 10.1007/s11886-023-01992-6 . free .
  40. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Lip GY, Dragan S, Mikhailidis DP . Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials . Mayo Clinic Proceedings . 90 . 1 . 24–34 . January 2015 . 25440725 . 10.1016/j.mayocp.2014.08.021 . Systematic Review and Meta-Analysis .
  41. Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ . Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials . Journal of the American Heart Association . 7 . 19 . e009835 . October 2018 . 30371340 . 6404871 . 10.1161/JAHA.118.009835 .
  42. Bhagavan HN, Chopra RK . Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics . Free Radical Research . 40 . 5 . 445–453 . May 2006 . 16551570 . 10.1080/10715760600617843 . 39001523 .
  43. Book: Bogentoft C, Edlund PO, Olsson B, Widlund L, Westensen K . Biopharmaceutical aspects of intravenous and oral administration of coenzyme Q10. . Biomedical and clinical aspects of coenzyme Q . 1991 . 6 . 215–224 .
  44. Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K . Improvement in intestinal coenzyme q10 absorption by food intake . Yakugaku Zasshi . 127 . 8 . 1251–1254 . August 2007 . 17666877 . 10.1248/yakushi.127.1251 . free . free . 2115/30144 .
  45. Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N . Pharmacokinetic study of deuterium-labeled coenzyme Q10 in man . International Journal of Clinical Pharmacology, Therapy, and Toxicology . 24 . 10 . 536–541 . October 1986 . 3781673 .
  46. 10.3390/antiox9050386. free . Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism . 2020 . Antioxidants . 9 . 5 . 386 . 32380795 . Mantle D, Dybring A . 7278738 .
  47. 10.3390/nu11030527. free . Bioavailability and Sustained Plasma Concentrations of CoQ10 in Healthy Volunteers by a Novel Oral Timed-Release Preparation . 2019 . Nutrients . 11 . 3 . 527 . 30823449 . 6471387 . Martucci A, Reurean-Pintilei D, Manole A .
  48. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C . Biologically erodable microspheres as potential oral drug delivery systems . Nature . 386 . 6623 . 410–414 . March 1997 . 9121559 . 10.1038/386410a0 . 4324209 . 1997Natur.386..410M .
  49. Hsu CH, Cui Z, Mumper RJ, Jay M . Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors . AAPS PharmSciTech . 4 . 3 . E32 . 2003 . 14621964 . 2750625 . 10.1208/pt040332 .
  50. Joshi SS, Sawant SV, Shedge A, Halpner AD . Comparative bioavailability of two novel coenzyme Q10 preparations in humans . International Journal of Clinical Pharmacology and Therapeutics . 41 . 1 . 42–48 . January 2003 . 12564745 . 10.5414/CPP41042 .
  51. Ozawa Y, Mizushima Y, Koyama I, Akimoto M, Yamagata Y, Hayashi H, Murayama H . Intestinal absorption enhancement of coenzyme Q10 with a lipid microsphere . Arzneimittel-Forschung . 36 . 4 . 689–690 . April 1986 . 3718593 .
  52. Westesen K, Siekmann B . Particles with modified physicochemical properties, their preparation and uses . US . 6197349 . 2001.
  53. Ohashi H, Takami T, Koyama N, Kogure Y, Ida K . Aqueous solution containing ubidecarenone . US . 4483873 . 1984.
  54. Zmitek J, Smidovnik A, Fir M, Prosek M, Zmitek K, Walczak J, Pravst I . Relative bioavailability of two forms of a novel water-soluble coenzyme Q10 . Annals of Nutrition & Metabolism . 52 . 4 . 281–287 . 2008 . 18645245 . 10.1159/000129661 . 825159 .
  55. Kagan D, Madhavi D . 2010 . A Study on the Bioavailability of a Novel Sustained-Release Coenzyme Q10-β-Cyclodextrin Complex . Integrative Medicine . 9 . 1.
  56. Wyman M, Leonard M, Morledge T . Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? . Cleveland Clinic Journal of Medicine . 77 . 7 . 435–442 . July 2010 . 20601617 . 10.3949/ccjm.77a.09078 . 26572524 . free .
  57. Hathcock JN, Shao A . Risk assessment for coenzyme Q10 (Ubiquinone) . Regulatory Toxicology and Pharmacology . 45 . 3 . 282–288 . August 2006 . 16814438 . 10.1016/j.yrtph.2006.05.006 .
  58. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM . Coenzyme Q10 and Heart Failure: A State-of-the-Art Review . Circulation: Heart Failure . 9 . 4 . e002639 . April 2016 . 27012265 . 10.1161/CIRCHEARTFAILURE.115.002639 . 2034503 . free .
  59. Pravst I, Zmitek K, Zmitek J . Coenzyme Q10 contents in foods and fortification strategies . Critical Reviews in Food Science and Nutrition . 50 . 4 . 269–280 . April 2010 . 20301015 . 10.1080/10408390902773037 . 38779392 .
  60. 10.1016/j.jfca.2011.03.018 . Ubiquinone contents in Korean fermented foods and average daily intakes . 2011 . Journal of Food Composition and Analysis . 24 . 8 . 1123–1129 . Pyo Y, Oh H .
  61. Weber C, Bysted A, Hłlmer G . The coenzyme Q10 content of the average Danish diet . International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition . 67 . 2 . 123–129 . 1997 . 9129255 .
  62. Morton RA . Ubiquinone . Nature . 182 . 4652 . 1764–1767 . December 1958 . 13622652 . 10.1038/1821764a0 . 1958Natur.182.1764M .
  63. Crane FL, Hatefi Y, Lester RL, Widmer C . Isolation of a quinone from beef heart mitochondria . Biochimica et Biophysica Acta . 25 . 1 . 220–221 . July 1957 . 13445756 . 10.1016/0006-3002(57)90457-2 .
  64. Wolf DE. 1958. Coenzyme Q. I. structure studies on the coenzyme Q group. Journal of the American Chemical Society. 80. 17. 4752. 10.1021/ja01550a096. 0002-7863.
  65. Mellors A, Tappel AL . Quinones and quinols as inhibitors of lipid peroxidation . Lipids . 1 . 4 . 282–284 . July 1966 . 17805631 . 10.1007/BF02531617 . 2129339 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Coenzyme Q10".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.